BridgeBio Pharma BBIO
Ownership & positioning
Who holds it, who is betting against it, and where the big money is moving
Short-sale volume as % of daily volume
Large-order net flow, last 20 sessions
Net of large-order buying minus selling, in USD. Over this window: +$34.85M (11 inflow days, 9 outflow days).
Net flow by order size, last 20 sessions
Super/Big orders approximate institutional-size trades; Mid/Small approximate retail-size trades. Net buy minus sell value in each bucket, summed over the window.
The five largest holders on file together own 29.8% of shares outstanding.
Largest holders
By investor type
Reported short interest has fallen from 11.93% to 10.70% of float over the last 6 biweekly reports (14 Aug 2026 to 30 Oct 2026).
Recent institutional activity
| Holder | Type | Period | Share change | New stake |
|---|---|---|---|---|
| Wellington Management Group | Mutual Fund | 2026/Q4 | +4,150,068 | 4.9% |
| Farallon Capital Management, L.L.C. | Hedge Fund | 2026/Q4 | +3,503,937 | 7.3% |
| Paradigm Biocapital Advisors LP | Hedge Fund | 2026/Q4 | +2,347,850 | 1.2% |
| J.P. Morgan Asset Management, Inc. | Mutual Fund | 2026/Q4 | +1,719,092 | 1.9% |
| Franklin Resources | Mutual Fund | 2026/Q4 | +1,118,756 | 1.7% |
| Deep Track Capital, LP | VC/PE Fund | 2026/Q4 | +885,882 | 0.5% |
| Hartford Funds Management Company, LLC | Mutual Fund | 2026/Q4 | +817,133 | 0.5% |
| AQR Capital Management | Hedge Fund | 2026/Q4 | +815,677 | 0.5% |
| Citigroup Inc. | Public Company | 2026/Q4 | +812,362 | 0.9% |
| UBS Asset Management | Mutual Fund | 2026/Q4 | +805,312 | 1.6% |
| Adage Capital Management, L.P. | Hedge Fund | 2026/Q4 | +779,958 | 1.6% |
| PRIMECAP Management Company | Mutual Fund | 2026/Q4 | +683,442 | 0.9% |
| Invesco Ltd. | Mutual Fund | 2026/Q4 | +611,527 | 2.1% |
| State Street Global Advisors | Mutual Fund | 2026/Q4 | +541,227 | 2.6% |
| Candriam, Société En Commandite Par Actions | Mutual Fund | 2026/Q4 | +402,325 | 0.4% |
Institutional buy/sell activity by reporting period, largest moves first.
Insider transactions
| Date | Insider | Title | Transaction | Shares | Price | Held after |
|---|---|---|---|---|---|---|
| 29 Oct 2026 | Maricel Apuli | Chief Accounting Officer | Automatic Disposition | -2,000 | $72.85 | 120,687 |
| 16 Sep 2026 | Neil Kumar | Chief Executive Officer | Automatic Disposition | -10,000 | $69.57 | 5,057,460 |
| 18 Aug 2026 | Neil Kumar | Chief Executive Officer | Automatic Disposition | -44,980 | $85.65 | 5,067,460 |
| 17 Aug 2026 | Neil Kumar | Chief Executive Officer | Intent to Sell (Form 144) | -34,980 | $79.89 | – |
| 16 Aug 2026 | Randal Scott | Former Independent Director | Intent to Sell (Form 144) | -21,501 | $79.86 | – |
| 15 Aug 2026 | Neil Kumar | Chief Executive Officer | Derivative Exercise and Sale | -36,237 | $79.86 | 5,112,440 |
| 15 Aug 2026 | Neil Kumar | Chief Executive Officer | Derivative Exercise and Retained | +34,980 | – | 5,112,440 |
| 15 Aug 2026 | Thomas Trimarchi | CFO & President | Sale to Issuer | -22,781 | $79.86 | 336,529 |
| 15 Aug 2026 | Maricel Apuli | Chief Accounting Officer | Sale to Issuer | -4,714 | $79.86 | 122,687 |
| 29 Jul 2026 | Maricel Apuli | Chief Accounting Officer | Automatic Disposition | -2,000 | $80.06 | 127,401 |
| 8 Jul 2026 | Jennifer Cook | Independent Director | Derivative Exercise and Sale | -148,589 | $90.00 | 8,383 |
| 8 Jul 2026 | Andrea Ellis | Independent Director | Derivative Exercise and Sale | -17,167 | $84.00 | 14,196 |
| 23 Jun 2026 | Randal Scott | Former Independent Director | Intent to Sell (Form 144) | -2,196 | $68.63 | – |
| 23 Jun 2026 | Jennifer Cook | Independent Director | Derivative Exercise and Sale | -37,167 | $70.00 | – |
| 22 Jun 2026 | Jennifer Cook | Independent Director | Automatic Disposition | -2,196 | $68.57 | – |
| 22 Jun 2026 | Hannah Valantine | Independent Director | Automatic Disposition | -2,196 | $68.57 | 1,274 |
| 21 Jun 2026 | Charles Homcy | Co-Founder, Chairman of Pharmaceuticals & Lead Director | Other Acquisition | +3,990 | – | 8,383 |
| 21 Jun 2026 | Charles Homcy | Co-Founder, Chairman of Pharmaceuticals & Lead Director | Other Derivative Acquisition | +5,277 | $68.92 | 5,277 |
| 21 Jun 2026 | Fred Hassan | Lead Independent Director | Other Acquisition | +3,990 | – | 8,383 |
| 21 Jun 2026 | Fred Hassan | Lead Independent Director | Other Derivative Acquisition | +5,277 | $68.92 | 5,277 |
From Form 4/Form 144 filings. Negative share counts are disposals (sales, gifts, or shares withheld for taxes); positive are acquisitions.
Short interest, by report
| Report date | Shares short | % of float | Days to cover |
|---|---|---|---|
| 30 Oct 2026 | 20,846,164 | 10.7% | 7.1 |
| 15 Oct 2026 | 19,997,556 | 10.2% | 7.7 |
| 30 Sep 2026 | 19,671,292 | 10.1% | 5.9 |
| 15 Sep 2026 | 21,549,349 | 11.0% | 10.5 |
| 31 Aug 2026 | 21,845,899 | 11.2% | 11.2 |
| 14 Aug 2026 | 23,324,059 | 11.9% | 10.8 |
No comments yet — be the first to weigh in on BBIO.
Sign in to join the discussion.